Evaluating Treatment Response in Laryngo-Pharyngeal Reflux

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although laryno-pharyngeal reflux (LPR) and gastroesophageal reflux disease (GERD) differ in symptoms and treatment, they are diagnosed by the same standard 24-hour pH monitoring system which measures liquid reflux in the esophagus. The investigators are evaluating a new 24-hour pharyngeal pH monitoring system by Restech which can measure acid exposure in the airway and can be used specifically for LPR diagnosis. The purpose of this study is to determine whether the Restech device is more effective than standard pH monitoring in predicting the response to proton pump inhibitor (PPI) acid suppression therapy using Dexlansoprazole in patients with symptoms and/or manifestations of LPR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)

NCT00321503

Laryngopharyngeal Reflux

COMPLETED

Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy

NCT01328652

Laryngopharyngeal Reflux Hypertrophy of Lingual Tonsil

UNKNOWN PHASE4

A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux

NCT01308502

Laryngopharyngeal Reflux

WITHDRAWN PHASE4

Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease

NCT02351960

Gastroesophageal Reflux Disease

COMPLETED PHASE4

Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux

NCT01854970

Laryngopharyngeal Reflux Oesophageal pH-impedance

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Laryngo-pharyngeal Reflux

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexlansoprazole

30mg a day, 3 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dexilant

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years old or above
* Have a clinical diagnosis of LPR
* Able and willing to provide consent

Exclusion Criteria

* History of any previous anti-reflux operation or procedure
* History of pharyngeal or laryngeal surgery
* History of larngeal or hypolaryngeal neoplasm
* Allergy or significant adverse reaction to PPI
* Patient on PPI therapy within 4 weeks prior to enrollment
* A cumulative history of PPI therapy equal to or greater than 3 months
* History of noncompliance with medication or study protocols
* Enrolled in another clinical trial using investigational medications

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No